Royal Bank Of Canada Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) Stock

Key Points

• Royal Bank of Canada raised Exelixis’ price target to $58 from $51 but maintained a “sector perform” rating; the target implies about 19% downside from the stock’s $71.63 price.
• Exelixis shares rose 8.2% to near a 52-week high after the company reported quarterly earnings of $0.94 per share and revenue of $658.7 million, both exceeding analyst expectations. Revenue increased 10.2% year over year.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and average price target of $53.21, despite several firms issuing Buy or Strong Buy ratings and institutional investors owning 85.27% of the stock.

Exelixis (NASDAQ:EXEL - Get Free Report) had its target price increased by equities research analysts at Royal Bank Of Canada from $51.00 to $58.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has a "sector perform" rating on the biotechnology company's stock. Royal Bank Of Canada's price objective would indicate a potential downside of 19.03% from the stock's current price.

Several other research firms have also recently weighed in on EXEL. Weiss Ratings raised shares of Exelixis from a "buy (a-)" rating to a "buy (a)" rating in a report on Thursday, October 8th. William Blair reissued an "outperform" rating on shares of Exelixis in a research report on Friday, September 11th. UBS Group set a $55.00 price objective on Exelixis in a research note on Monday, August 3rd. Citizens Jmp boosted their price target on shares of Exelixis from $55.00 to $65.00 and gave the stock a "market outperform" rating in a research note on Monday, October 19th. Finally, Wall Street Zen upgraded Exelixis from a "buy" rating to a "strong-buy" rating in a report on Saturday, October 24th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $53.21.

Exelixis Stock Up 8.2%

Shares of NASDAQ:EXEL traded up $5.43 on Friday, hitting $71.63. The company had a trading volume of 1,367,105 shares, compared to its average volume of 2,570,686. Exelixis has a 1 year low of $36.00 and a 1 year high of $71.87. The firm has a market capitalization of $17.75 billion, a price-to-earnings ratio of 22.59, a P/E/G ratio of 1.86 and a beta of 0.47. The firm's 50-day simple moving average is $59.07 and its two-hundred day simple moving average is $50.79.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biotechnology company reported $0.94 earnings per share for the quarter, topping analysts' consensus estimates of $0.89 by $0.05. The business had revenue of $658.70 million for the quarter, compared to analysts' expectations of $646.51 million. Exelixis had a net margin of 35.33% and a return on equity of 42.17%. The business's revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.78 earnings per share. Equities research analysts anticipate that Exelixis will post 3.19 EPS for the current year.

Insider Buying and Selling at Exelixis

In related news, Director Mary Beckerle sold 9,812 shares of the firm's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $53.66, for a total transaction of $526,511.92. Following the sale, the director directly owned 16,079 shares of the company's stock, valued at $862,799.14. This trade represents a 37.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.60% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of EXEL. BlackRock Inc. purchased a new stake in shares of Exelixis in the second quarter valued at $1,581,991,000. Caisse de depot et placement du Quebec purchased a new position in shares of Exelixis in the 2nd quarter worth about $113,951,000. Bank of New York Mellon Corp acquired a new stake in Exelixis during the 2nd quarter worth approximately $107,803,000. Jupiter Topco LLC acquired a new stake in shares of Exelixis in the second quarter worth $67,299,000. Finally, First Trust Advisors LP boosted its position in Exelixis by 62.0% during the 1st quarter. First Trust Advisors LP now owns 2,534,992 shares of the biotechnology company's stock worth $108,726,000 after purchasing an additional 970,144 shares during the period. 85.27% of the stock is owned by hedge funds and other institutional investors.

More Exelixis News

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q3 earnings and revenue exceeded expectations. Exelixis reported non-GAAP earnings of $0.94 per share, above the $0.89 consensus estimate, while revenue reached $658.7 million versus expectations of approximately $646.5 million. Revenue grew 10.2% year over year, with CABOMETYX continuing to drive performance. Exelixis Q3 Earnings Report
• Positive Sentiment: Pipeline progress provides a potential catalyst. Exelixis said the FDA has assigned a March 3, 2027 PDUFA date for zanzalintinib, giving investors a defined timeline for a regulatory decision. The company is also advancing Wave 2 pivotal development plans, which could expand its future growth opportunities. Zanzalintinib PDUFA and Wave 2 Plans
• Positive Sentiment: Profitability and cash generation remained strong. Third-quarter net income increased year over year, and operating cash flow totaled about $280 million, reinforcing Exelixis’ ability to fund its commercial operations and pipeline.
• Neutral Sentiment: Institutional positioning was mixed. Recent filings showed significant purchases by some quantitative and institutional investors, while other large managers reduced their holdings. This signals differing views on the stock’s valuation and outlook.
• Negative Sentiment: Barclays remains cautious on valuation. The firm raised its price target from $49 to $54 but maintained an “equal weight” rating. The new target remains materially below the recent trading level, suggesting limited near-term upside in Barclays’ view.
• Negative Sentiment: Reported insider activity has been entirely selling. Data cited in recent coverage showed six insider sales and no purchases during the past six months. While these transactions may be routine, they can weigh on investor sentiment when the stock is near a 52-week high.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer and other serious diseases. The company's research programs center primarily on targeted therapies, including treatments designed to inhibit signaling pathways involved in tumor growth and progression.

Exelixis' lead product is CABOMETYX (cabozantinib), an oral medicine approved in the United States for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.